(Q47736967)

5 February 2018

title

Potential drug-drug interactions on a tertiary-care hospital consultation-liaison psychiatry service (English)

1 reference

5 February 2018

0 references

0 references

Adson DE

1

1 reference

5 February 2018

Crow SJ

series ordinal

2

1 reference

5 February 2018

Meller WH

series ordinal

3

1 reference

5 February 2018

Magraw RM

series ordinal

4

1 reference

5 February 2018

publication date

1 July 1998

1 reference

5 February 2018

published in

Psychosomatics

1 reference

5 February 2018

volume

39

1 reference

5 February 2018

issue

4

1 reference

5 February 2018

page(s)

360-365

1 reference

5 February 2018

The emerging role of cytochrome P450 3A in psychopharmacology

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

The clinician and drug interactions--an update

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

Recent developments in drug metabolism of relevance to psychiatrists

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

Newer antidepressants and the cytochrome P450 system

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

Drug-drug interactions involving antidepressants: focus on venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

An interaction of sertraline and desipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-3182%2898%2971324-6

7 January 2021

10.1016/S0033-3182(98)71324-6

Identifiers

DOI

0 references

1 reference

5 February 2018